First-in-human study of Elvn-001, a highly selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed previous tyrosine kinase inhibitor therapies Meeting Abstract
| Authors: | Hughes, T.; Mauro, M.; Branford, S.; Deng, W.; Wang, Q.; Collins, H.; Hochhaus, A. |
| Abstract Title: | First-in-human study of Elvn-001, a highly selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed previous tyrosine kinase inhibitor therapies |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6780 |
| End Page: | 6781 |
| Language: | English |
| ACCESSION: | WOS:000893223206354 |
| DOI: | 10.1182/blood-2022-170401 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
